Looks like they released it in Australia yesterday, not a bad report considering there are no new markets contributing yet. And on the last newsletter, as usual, they were not very clear on what is needed and when they anticipate being able to actually sell in the US. It’s been a frustrating few months since US approval, hopefully tangible good news (Australian approval, treatment / sales in US starting) starts coming soon.